Ä«Å×°í¸®
|
Cytokines & Growth Factor
|
CAT.NO
|
LGP-11-012
|
PRODUCT
|
Flt-3 Ligand, Rhesus (Macaque Fms-related Tyrosine Kinase 3 Ligand)
|
SIZE
|
10ug, 100ug, 250ug
|
PRICE
|
KRW 285,000, 1,595,000, 2,622,000
|
Technical Parameters
Synonyms |
Flt3L, SL cytokine |
Accession |
H9Z6V7 |
GeneID |
719239 |
Source |
Escherichia coli. |
Molecular Weight |
Approximately 18.0 kDa, a single non-glycosylated polypeptide chain containing 159 amino acids. |
Quantity |
10µg/100µg/250µg |
AA Sequence |
TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVPSNLQD EELCGALWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQHP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPRSPGALEA TALTAPQRP |
Purity |
> 97 % by SDS-PAGE and HPLC analyses. |
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human AML5 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 ¡¿ 106 IU/mg. |
Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
Formulation |
Lyophilized from a 0.2 ¥ìm filtered solution in PBS, pH 7.4. |
Endotoxin |
Less than 1 EU/¥ìg of rRhFlt-3L as determined by LAL method. |
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ¡Â -20 ¡ÆC. Further dilutions should be made in appropriate buffered solutions. |
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 ¡ÆC as supplied. - 1 month, 2 to 8 ¡ÆC under sterile conditions after reconstitution. - 3 months, -20 to -70 ¡ÆC under sterile conditions after reconstitution. |
Usage |
This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. |
SDS-PAGE |
|
Reference |
1. Hacein-Bey S, Basile GD, Lemerle J, et al. 1998. Blood, 92: 4090-7. 2. Peters M, Solem F, Goldschmidt J, et al. 2001. Exp Hematol, 29: 146-55. 3. Beq S, Fontanet A, Theze J, et al. 2004. AIDS, 18: 2089-91. 4. Mahadevan D, Choi J, Cooke L, et al. 2009. Hum Genomics Proteomics, 2009: 453634. 5. Coates PT, Barratt-Boyes SM, Zhang L, et al. 2003. Blood, 102: 2513-21. |
Background |
Flt-3 ligand (FL) is a recently identified hematopoietic cytokine whose activities are mediated by binding to the transmembrane glycoprotein Flt-3. Flt-3 was first discovered as a member of the class III subfamily of receptor tyrosine kinases (RTK) whose expression among hematopoietic cells was found to be restricted to highly enriched stem/progenitor cell populations. Additionally, class III RTKs include the receptors from SCF, M-CSF and PDGF. Not surprisingly, Flt-3 ligand is also structurally related to M-CSF and SCF. All three cytokines have been shown to exist both as type I transmembrane proteins and as soluble proteins. The predominant human FL isoform is a transmembrane protein that can undergo proteolytic cleavage to generate a soluble form of the protein. FL has been shown to synergize with a wide variety of hematopoietic cytokines to stimulate the growth and differentiation of early hematopoietic progenitors. |
|
÷ºÎÆÄÀÏ
|
|
|
|
|